Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1855, Issue 1, 2015, Pages 1-16

  Joosten, S C ^a   Hamming, L ^a   Soetekouw, P M ^a   Aarts, M J ^a   Veeck, J ^a,b   van Engeland, M ^a   Tjan Heijnen, V C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Biological tumor markers; Drug resistance; Kidney cancer; Renal cell carcinoma; Sunitinib; Targeted therapy

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; CABOZANTINIB; CEDIRANIB; DOVITINIB; EPIDERMAL GROWTH FACTOR; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MEDI 0639; MITOGEN ACTIVATED PROTEIN KINASE; MK 0752; MULTIDRUG RESISTANCE PROTEIN 1; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; N DEETHYLSUNITINIB; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR C; SCATTER FACTOR; SORAFENIB; SPHINGOSINE KINASE 1; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR MARKER;

ABCB1 GENE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CASTRATION RESISTANT PROSTATE CANCER; CD11B + GR1+ MYELOID CELL; DNA METHYLATION; DOWN REGULATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE; GENE INACTIVATION; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; METASTASIS; NONHUMAN; OUTCOME ASSESSMENT; PERICYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION; VHL GENE; CARCINOMA, RENAL CELL; DRUG RESISTANCE; GENETICS; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PYRROLES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84911915182     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.11.002     Document Type: Review

References (176)

1. Lopez-Beltran A., Scarpelli M., Montironi R., Kirkali Z. 2004 WHO classification of the renal tumors of adults. Eur. Urol. 2006, 49:798-805.
2. Baldewijns M.M., van Vlodrop I.J., Schouten L.J., Soetekouw P.M., de Bruine A.P., van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim. Biophys. Acta 2008, 1758:133-155.
3. Rydzanicz M., Wrzesinski T., Bluyssen H.A., Wesoly J. Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications. Cancer Lett. 2013, 341:111-126.
4. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., Latif F., Liu S., Chen F., Duh F.M., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 1994, 7:85-90.
5. Banks R.E., Tirukonda P., Taylor C., Hornigold N., Astuti D., Cohen D., Maher E.R., Stanley A.J., Harnden P., Joyce A., Knowles M., Selby P.J. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006, 66:2000-2011.
6. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 2007, 6:734-745.
7. Huang D., Ding Y., Li Y., Luo W.M., Zhang Z.F., Snider J., VandenBeldt K., Qian C., Teh B.T. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 2010, 70:1053-1062.
8. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A., Garcia-del-Muro X., Sosman J.A., Solska E., Wilding G., Thompson J.A., Kim S.T., Chen I., Huang X., Figlin R.A. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27:3584-3590.
9. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., Rini B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24:16-24.
10. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., Redman B.G., Margolin K.A., Merchan J.R., Wilding G., Ginsberg M.S., Bacik J., Kim S.T., Baum C.M., Michaelson M.D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
11. Molina A.M., Lin X., Korytowsky B., Matczak E., Lechuga M.J., Wiltshire R., Motzer R.J. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur. J. Cancer 2014, 50:351-358.
12. Rini B.I., Atkins M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009, 10:992-1000.
13. Motzer R.J., Hutson T.E., Cella D., Reeves J., Hawkins R., Guo J., Nathan P., Staehler M., de Souza P., Merchan J.R., Boleti E., Fife K., Jin J., Jones R., Uemura H., De Giorgi U., Harmenberg U., Wang J., Sternberg C.N., Deen K., McCann L., Hackshaw M.D., Crescenzo R., Pandite L.N., Choueiri T.K. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 2013, 369:722-731.
14. Escudier B., Porta C., Bono P., Powles T., Eisen T., Sternberg C.N., Gschwend J.E., De Giorgi U., Parikh O., Hawkins R., Sevin E., Negrier S., Khan S., Diaz J., Redhu S., Mehmud F., Cella D. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J. Clin. Oncol. 2014, 32:1412-1418.
15. Shannon A.M., Bouchier-Hayes D.J., Condron C.M., Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 2003, 29:297-307.
16. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
17. Baldewijns M.M., van Vlodrop I.J., Vermeulen P.B., Soetekouw P.M., van Engeland M., de Bruine A.P. VHL and HIF signaling in renal cell carcinogenesis. J. Pathol. 2010, 221:125-138.
18. Richard S., Gardie B., Couvé S., Gad S. Von Hippel-Lindau: how a rare disease illuminates cancer biology. Semin. Cancer Biol. 2013, 23:26-37.
19. Shen C., Kaelin W.G. The VHL/HIF axis in clear cell renal carcinoma. Semin. Cancer Biol. 2013, 23:18-25.
20. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
21. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., Ancukiewicz M., Mrugala M.M., Plotkin S., Drappatz J., Louis D.N., Ivy P., Scadden D.T., Benner T., Loeffer J.S., Wen P.Y., Jain R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
22. Sun J.D., Liu Q., Wang J., Ahluwalia D., Ferraro D., Wang Y., Duan J.X., Ammons W.S., Curd J.G., Matteucci M.D., Hart C.P. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibitis tumor growth in preclinical models of cancer. Clin. Cancer Res. 2012, 18:758-770.
23. Meng F., Evans J.W., Bhupathi D., Banica M., Lan L., Lorente G., Duan J.X., Cai X., Mowday A.M., Guise C.P., Maroz A., Anderson R.F., Patterson A.V., Stachelek G.C., Glazer P.M., Matteucci M.D., Hart C.P. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol. Cancer Ther. 2012, 11:740-751.
24. Portwood S., Lal D., Hsu Y.C., Vargas R., Johnson M.K., Wetzler M., Hart C.P., Wang E.S. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia (AML) models. Clin. Cancer Res. 2013, 19:6506-6519.
25. Hu J., van Valckenborgh E., Xu D., Menu E., de Raeve H., de Bryune E., Xu S., van Camp B., Handisides D., Hart C.P., Vanderkerken K. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. Mol. Cancer Ther. 2013, 12:1763-1773.
26. Liu Q., Sun J.D., Wan J., Ahluwalia D., Baker A.F., Cranmer L.D., Ferraro D., Wang Y., Fuan J.X., Ammons W.S., Curd J.G., Matteucci M.D., Hart C.P. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother. Pharmacol. 2012, 69:1487-1498.
27. Ganjoo K.N., Cranmer L.D., Butrynski J.E., Rushing D., Adkins D., Okuno S.H., Lorente G., Kroll S., Langmuir V.K., Chawla S.P. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology 2011, 80:50-56.
28. Weiss G.J., Infante J.R., Chiorean E.G., Borad M.J., Bendell J.C., Molina J.R., Tibes R., Ramanathan R.K., Lewandowski K., Jones S.F., Lacouture M.E., Langmuir V.K., Lee H., Kroll S., Burris H.A. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin. Cancer Res. 2011, 17:2997-3004.
29. Welti J.C., Gourlaouen M., Powles T., Kudahetti S.C., Wilson P., Berney D.M., Reynolds A.R. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2011, 30:1183-1193.
30. Motzer R.J., Porta C., Vogelzang N.J., Sternberg C.N., Szczylik C., Zolnierek J., Kollmannsberger C., Rha S.Y., Bjarnason G.A., Melichar B., De Giorgi U., Grunwald V., Davis I.D., Lee J.L., Esteban E., Urbanowitz G., Cai C., Squires M., Marker M., Shi M.M., Escudier B. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014, 15:286-296.
31. Schmidinger M. Third-line dovitinib in metastatic renal cell carcinoma. Lancet Oncol. 2014, 15:245-246.
32. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A.A., Rolland F., Demkow T., Hutson T.E., Gore M., Freeman S., Schwartz B., Shan M., Simantov R., Bukowski R.M. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356:125-134.
33. Huang D., Ding Y., Zhou M., Rini B.I., Petillo D., Qian C.N., Kahnoski R., Futreal P.A., Furge K.A., Teh B.T. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010, 70:1063-1071.
34. Mizukami Y., Jo W.S., Duerr E.M., Gala M., Li J., Zhang X., Zimmer M.A., Iliopoulos O., Zukerberg L.R., Kohgo Y., Lynch M.P., Rueda B.R., Chung D.C. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 2005, 11:992-997.
35. Wysoczynski M., Shin D.M., Kucia M., Ratajczak M.Z. Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications. Int. J. Cancer 2010, 126:371-381.
36. Martin D., Galisteo R., Gutkind J.S. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkB trough the CBM (Carma3/Bcl10/Malt1) complex. J. Biol. Chem. 2009, 284:6038-6042.
37. Loges S., Schmidt T., Carmeliet P. "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF. Clin. Cancer Res. 2009, 15:3648-3653.
38. Ribatti D. The controversial role of placental growth factor in tumor growth. Cancer Lett. 2011, 307:1-5.
39. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., de Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche T., Ponten A., Eriksson U., Plate K.H., Foidart J.M., Schaper W., Charnock-Jones D.S., Hicklin D.J., Herbert J.M., Collen D., Persico M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001, 7:575-583.
40. Kim K.J., Cho C.S., Kim W.U. Role of placenta growth factor in cancer and inflammation. Exp. Mol. Med. 2012, 44:10-19.
41. Zhang L., Chen J., Ke Y., Mansel R.E., Jiang W.G. Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J. Surg. Oncol. 2005, 3:68.
42. Wei S.C., Tsao P.N., Yu S.C., Shun C.T., Tsai-Wu J.J., Wu C.H., Su Y.N., Hsieh F.J., Wong J.M. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 2005, 54:666-672.
43. Parr C., Watkins G., Boulton M., Cai J., Jiang W.G. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur. J. Cancer 2005, 41:2819-2827.
44. Chen C.N., Hsieh F.J., Cheng Y.M., Cheng W.F., Su Y.N., Chang K.J., Lee P.H. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett. 2004, 213:73-82.
45. Takahashi A., Sasaki H., Kim S.J., Tobisu K., Kakizoe T., Tsukamoto T., Kumamoto Y., Sugimura T., Terada M. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994, 54:4233-4237.
46. Matsumoto K., Suzuki K., Koike H., Okamura K., Tsuchiya K., Uchida T., Takezawa Y., Kobayashi M., Yamanaka H. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res. 2003, 23:4953-4958.
47. Bagley R.G., Ren Y., Weber W., Yao M., Kurtzberg L., Pinckney J., Bangari D., Nguyen C., Brondyk W., Kaplan J., Teicher B.A. Placental Growth Factor upregulation is a host response to antiangiogenic therapy. Clin. Cancer Res. 2011, 17:976-988.
48. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., de Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van Rooijen N., Giacca M., Stassen J.M., Dewerchin M., Collen D., Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
49. Eriksson A., Cao R., Pawliuk R., Berg S.M., Tsang M., Zhou D., Fleet C., Tritsaris K., Dissing S., Leboulch P., Cao Y. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2002, 1:99-108.
50. Xu L., Cochran D.M., Tong R.T., Winkler F., Kashiwagi S., Jain R.K., Fukumura D. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res. 2006, 66:3971-3977.
51. Hedlund E.M.E., Yang X., Zhang Y., Yang Y., Shibuya M., Zhong W., Sun B., Liu Y., Hosaka K., Cao Y. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:654-659.
52. Currie M.J., Gunningham S.P., Turner K., Han C., Scott P.A.E., Robinson B.A., Chong W., Harris A.L., Fox S.B. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J. Pathol. 2002, 198:502-510.
53. Bullock A.J., Zhang L., O'Neill A., Percy A., Sukhatme V., Mier J., Atkins M., Bhatt R. Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC). J. Clin. Oncol. 2010, 28. (Abstract: 4630).
54. Hu B., Cheng S.Y. Angiopoietin-2: development of inhibitors for cancer therapy. Curr. Oncol. Rep. 2009, 11:111-116.
55. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., Yancopoulos G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
56. Leow C.C., Coffman K., Inigo I., Breen S., Czapiga M., Soukharev S., Gingles N., Peterson N., Fazenbaker C., Woods R., Jallal B., Ricketts S.A., Lavallee T., Coats S., Chang Y. MEDI3617, a human anti-Angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int. J. Oncol. 2012, 40:1321-1330.
57. Brown J.L., Cao Z.A., Pinzon-Ortiz M., Kendrew J., Reimer C., Wen S., Zhou J.Q., Tabrizi M., Emery S., McDermott B., Pablo L., McCoon P., Bedian V., Blakey D.C. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol. Cancer Ther. 2010, 9:145-156.
58. Koh Y.J., Kim H.Z., Hwang S.I., Lee J.E., Oh N., Jung K., Kim M., Kim K.E., Kim H., Lim N.K., Jeon C.J., Lee G.M., Jeon B.H., Nam D.H., Sung H.K., Nagy A., Yoo O.J., Koh G.Y. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 2010, 18:171-184.
59. Patel N.S., Li J.L., Generali D., Poulsom R., Cranston D.W., Harris A.L. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 2005, 65:8690-8697.
60. Mailhos C., Modlich U., Lewis J., Harris A., Bicknell R., Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001, 69:135-144.
61. Gale N.W., Dominguez M.G., Noguera I., Pan L., Hughes V., Valenzuela D.M., Murphy A.J., Adams N.C., Lin H.C., Holash J., Thurston G., Yancopoulos G.D. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15949-15954.
62. Noguera-Troise I., Daly C., Papadopoulos N., Coetzee S., Boland P., Gale N.W., Lin H.C., Yancopoulos G.D., Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444:1032-1037.
63. Kuhnert F., Kirshner J.R., Thurston G. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc. Cell 2011, 3:20.
64. Ridgway J., Zhang G., Wu Y., Stawicki S., Liang W.C., Chanthery Y., Kowalski J., Watts R.J., Callahan C., Kasman I., Singh M., Chien M., Tan C., Hongo J.A., de Sauvage F., Plowman G., Yan M. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444:1083-1087.
65. Yan M., Plowman G.D. Delta-like 4/Notch signaling and its therapeutic implications. Clin. Cancer Res. 2007, 13:7243-7246.
66. Tolcher A.W., Messersmith W.A., Mikulski S.M., Papadopoulos K.P., Kwak E.L., Gibbon D.G., Patnaik A., Falchook G.S., Dasari A., Shapiro G.I., Boylan J.F., Xu Z.X., Wang K., Koehler A., Song J., Middleton S.A., Deutsch J., DeMario M., Kurzrock R., Wheler J.J. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol. 2012, 30:2348-2353.
67. Krop I., Demuth T., Guthrie T., Wen P.Y., Mason W.P., Chinnaiyan P., Butowski N., Groves M.D., Kesari S., Freedman S.J., Blackman S., Watters J., Loboda A., Podtelezhnikov A., Lunceford J., Chen C., Giannotti M., Hing J., Beckman R., LoRusso P. Phase I pharmacological and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 2012, 30:2307-2313.
68. Sahebjam S., Bedard P.L., Castonguay V., Chen Z., Reedijk M., Liu G., Cohen B., Zhang W.J., Clarke B., Zhang T., Kamel-Reid S., Chen H., Ivy S.P., Razak A.R.A., Oza A.M., Chen E.X., Hirte H.W., McGarrity A., Wang L., Siu L.L., Hotte S.J. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br. J. Cancer 2013, 109:943-949.
69. Diaz-Padilla I., Hirte H., Oza A.M., Clarke B.A., Cohen B., Reedijk M., Zhang T., Kamel-Reid S., Ivy S.P., Hotte S.J., Razak A.A.R., Chen E.X., Brana I., Wizemann M., Wang L., Siu L.L., Bedard P.L. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest. New Drugs 2013, 31:1182-1191.
70. Richter S., Bedard P.L., Chen E.X., Clarke B.A., Tran B., Hotte S.J., Stathis A., Hirte H.W., Razak A.R.A., Reedijk M., Chen Z., Cohen B., Zhang W.J., Wang L., Ivy S.P., Moore M.J., Oza A.M., Siu L.L., McWhirter E. A phase I study of the oral gamma secretase inhibitor RO4929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest. New Drugs 2013, 32:243-249.
71. Huang Q.B., Ma X., Li H.Z., Ai Q., Liu S.W., Zhang Y., Gao Y., Fan Y., Ni D., Wang B.J., Zhang X. Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis. Oncotarget 2014, 5:3066-3075.
72. Hu G.H., Liu H., Lai P., Guo Z.F., Xu L., Yao X.D., Zheng J.H., Liu M., Xu Y.F. Delta-like ligand 4 (Dll4) predicts the prognosis of clear cell renal cell carcinoma, and anti-Dll4 suppresses tumor growth in vivo. Int. J. Clin. Exp. Pathol. 2014, 7:2143-2152.
73. Shojaei F., Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist. Updat. 2008, 11:219-230.
74. Crawford Y., Ferrara N. Tumor and stromal pathways medating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol. Sci. 2009, 30:624-630.
75. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegué E., Song H., Vandenberg S., Johnson R.S., Werb Z., Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
76. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., Capla J.M., Galiano R.D., Levine J.P., Gurtner G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 2004, 10:858-864.
77. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8:592-603.
78. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
79. Palma M.D., Venneri M.A., Galli R., Sergi L.S., Politi L.S., Sampaolesi M., Naldini L. Tie2 indentifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
80. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
81. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N.R., Crystal R.G., Moore M.A.S., Hajjar K.A., Manova K., Benezra R., Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursors block tumor angiogenesis and growth. Nat. Med. 2001, 7:1194-1201.
82. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L.M., Carbone D.P., Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.
83. Cirri P., Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am. J. Cancer Res. 2011, 1:482-497.
84. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
85. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., Kaminker J., Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15:21-34.
86. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
87. Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., Blanchard D., Bais C., Peale F.V., van Bruggen N., Ho C., Ross J., Tan M., Carano R.A.D., Meng Y.G., Ferrara N. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-834.
88. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., Meng Y.G., Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6742-6747.
89. Panka D.J., Liu Q., Geissler A.K., Mier J.W. Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. Mol. Cancer 2013, 12:17.
90. Bergers G., Song S. The role of pericytes in blood-vessel formation and maintenance. J. Neuro Oncol. 2005, 7:452-464.
91. Ellis L.M., Hicklin D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin. Cancer Res. 2008, 14:6371-6375.
92. Reinmuth N., Liu W., Jung Y.D., Ahmad S.A., Shaheen R.M., Fan F., Bucana C.D., McMahon G., Gallick G.E., Ellis L.M. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 2001, 15:1239-1241.
93. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999, 103:159-165.
94. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111:1287-1295.
95. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., Menger M.D., Ullrich A., Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2003, 18:338-340.
96. Shaheen R.M., Tseng W.W., Davis D.W., Liu W., Reinmuth N., Vellagas R., Wieczorek A.A., Ogura Y., McConkey D.J., Drazan K.E., Bucana C.D., McMahon G., Ellis L.M. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 2001, 61:1464-1468.
97. Xian X., Hakansson J., Stahlberg A., Lindblom P., Betsholtz C., Gerhardt H., Semb H. Pericytes limit tumor cell metastasis. J. Clin. Invest. 2006, 116:642-651.
98. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
99. Ebos J.M.L., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
100. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
101. Loges S., Mazzone M., Hohensinner P., Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009, 15:167-170.
102. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
103. Shojaei F., Lee J.H., Simmons B.H., Wong A., Esparza C.O., Plumlee P.A., Feng J., Stewart A.E., Hu-Lowe D.D., Christensen J.G. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010, 70:10090-10100.
104. Koochekpour S., Jeffers M., Wang P.H., Gong C., Taylor G.A., Roessler L.M., Stearman R., Vasselli J.R., Stetler-Stevenson W.G., Kaelin W.G., Linehan W.M., Klausner R.D., Gnarra J.R., Vande Woude G.F. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell. Biol. 1999, 19:5902-5912.
105. Zhang Y.W., Su Y., Volpert O.V., Vande Woude G.F. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12718-12723.
106. Ide T., Kitajima Y., Miyoshi A., Ohtsuka T., Mitsuno M., Ohtaka K., Koga Y., Miyazaki K. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int. J. Cancer 2006, 119:2750-2759.
107. Lu K.V., Chang J.P., Parachoniak C.A., Pandika M.M., Aghi M.K., Meyronet D., Isachenko N., Fouse S.D., Phillips J.J., Cheresh D.A., Park M., Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012, 22:21-35.
108. Sennino B., Ishiguro-Oonuma T., Wei Y., Naylor R.M., Williamson C.W., Bhagwandin V., Tabruyn S.P., You W.K., Chapman H.A., Christensen J.G., Aftab D.T., McDonald D.M. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012, 2:270-287.
109. Hammers H.J., Verheul H.M., Salumbides B., Sharma R., Rudek M., Jaspers J., Shah P., Ellis L., Shen L., Paesante S., Dykema K., Furge K., Teh B.T., Netto G., Pili R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol. Cancer Ther. 2010, 9:1525-1535.
110. Shojaei F., Simmons B.H., Lee J.H., Lappin P.B., Christensen J.G. HGF-c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett. 2012, 320:48-55.
111. Yakes F.M., Chen J., Tan J., Yamaguchi K., Shi Y., Yu P., Qian F., Chu F., Bentzien F., Cancilla B., Orf J., You A., Laird A.D., Engst S., Lee L., Lesch J., Chou Y.C., Joly A.H. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 2011, 10:2298-2308.
112. Choueiri T.K., Pal S.K., McDermott D.F., Ramies D.A., Morrissey S., Lee Y., Miles D., Holland J., Dutcher J.P. Efficacy of cabozantinib (XL184) in patients with metastatic, refractory renal cell carcinoma. J. Clin. Oncol. 2012, 30. (abstr 4504).
113. Smith D.C., Smith M.R., Sweeney C., Elfiky A.A., Logothetis C., Corn P.G., Vogelzang N.J., Small E.J., Harzstark A.L., Gordon M.S., Vaishampayan U.N., Haas N.B., Spira A.I., Lara P.N., Lin C.C., Srinivas S., Sella A., Schoffski P., Scheffold C., Weitzman A.L., Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J. Clin. Oncol. 2013, 31:412-419.
114. Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma. Curr. Oncol. Rep. 2013, 15:76-82.
115. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9:327-337.
116. Gao H., Deng L. Sphingosine kinase-1 activation causes acquired resistance against sunitinib in renal cell carcinoma cells. Cell Biochem. Biophys. 2014, 68:419-425.
117. Cuvillier O., Ader I., Bouquerel P., Brizuela L., Malavaud B., Mazerolles C., Rischmann P. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr. Mol. Pharmacol. 2010, 3:53-65.
118. Ader I., Brizuela L., Bouquerel P., Malavaud B., Cuvillier O. Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1 α during hypoxia in human cancer cells. Cancer Res. 2008, 68:8635-8642.
119. Visentin B., Vekich J.A., Sibbald B.J., Cavalli A.L., Moreno K.M., Matteo R.G., Garland W.A., Lu Y., Yu S., Hall H.S., Kundra V., Mills G.B., Sabbadini R.A. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006, 9:225-238.
120. van der Veldt A.A., Eechoute K., Gelderblom H., Gietema J., Guchelaar H.J., van Erp N.P., van den Eertwegh A.J., Haanen J.B., Mathijssen R.H., Wessels J.A. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res. 2011, 17:620-629.
121. Beuselinck B., Karadimou A., Lambrechts D., Claes B., Wolter P., Couchy G., Berkers J., Paridaens R., Schoffski P., Mejean A., Verkarre V., Lerut E., de la Taille A., Tourani J.M., Bigot P., Linassier C., Negrier S., Berger J., Patard J.J., Zucman-Rossi J., Oudard S. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 2013, 108:887-900.
122. Garcia-Donas J., Esteban E., Leandro-Garcia L.J., Castellano D.E., del Alba A.G., Climent M.A., Arranz J.A., Gallardo E., Puente J., Bellmunt J., Mellado B., Martinez E., Moreno F., Font A., Robledo M., Rodriguez-Antona C. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011, 12:1143-1150.
123. Beuselinck B., Karadimou A., Lambrechts D., Claes B., Wolter P., Couchy G., Berkers J., van Poppel H., Paridaens R., Schoffski P., Mejean A., Verkarre V., Lerut E., Joly F., Lebret T., Gravis G., Deplanque G., Descazeaud A., Leclercq N.R., Molinie V., Patard J.J., Teghom C., Elaidi R., Zucman-Rossi J., Oudard S. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib-a multicentric retrospective analysis. Acta Oncol. 2014, 53:103-112.
124. Scartozzi M., Bianconi M., Faloppi L., Loretelli C., Bittoni A., Del Prete M., Giampieri R., Maccaroni E., Nicoletti S., Burattini L., Minardi D., Muzzonigro G., Montironi R., Cascinu S. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br. J. Cancer 2013, 108:1126-1132.
125. Kim J.J., Vaziri S.A., Rini B.I., Elson P., Garcia J.A., Wirka R., Dreicer R., Ganapathi M.K., Ganapathi R. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 2012, 118:1946-1954.
126. Gotink K.J., Broxterman H.J., Labots M., de Haas R.R., Dekker H., Honeywell R.J., Rudek M.A., Beerepot L.V., Musters R.J., Jansen G., Griffioen A.W., Assaraf Y.G., Pili R., Peters G.J., Verheul H.M.W. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin. Cancer Res. 2011, 17:7337-7346.
127. Zama I.N., Hutson T.E., Elson P., Cleary J.M., Choueiri T.K., Heng D.Y., Ramaiya N., Michaelson M.D., Garcia J.A., Knox J.J., Escudier B., Rini B.I. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010, 116:5400-5406.
128. Grunwald V., Weikert S., Seidel C., Busch J., Johannsen A., Fenner M., Reuter C., Ganser A., Johannsen M. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie 2011, 34:310-314.
129. Petillo D., Kort E.J., Anema J., Furge K.A., Yang X.J., Teh B.T. MicroRNA profiling of human kidney cancer subtypes. Int. J. Oncol. 2009, 35:109-114.
130. Nakada C., Matsuura K., Tsukamoto Y., Tanigawa M., Yoshimoto T., Narimatsu T., Nguyen L.T., Hijiya N., Uchida T., Sato F., Mimata H., Seto M., Moriyama M. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J. Pathol. 2008, 216:418-427.
131. Chow T.F., Youssef Y.M., Lianidou E., Romaschin A.D., Honey R.J., Stewart R., Pace K.T., Yousef G.M. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin. Biochem. 2010, 43:150-158.
132. Gamez-Pozo A., Anton-Aparicio L.M., Bayona C., Borrega P., Gallegos Sancho M.I., Garcia-Dominguez R., de Portugal T., Ramos-Vazquez M., Perez-Carrion R., Bolos M.V., Madero R., Sanchez-Navarro I., Fresno Vara J.A., Espinosa Arranz E. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 2012, 14:1144-1152.
133. Prior C., Perez-Gracia J.L., Garcia-Donas J., Rodriguez-Antona C., Guruceaga E., Esteban E., Suarez C., Castellano D., del Alba A.G., Lozano M.D., Carles J., Climent M.A., Arranz J.A., Gallardo E., Puente J., Bellmunt J., Gurpide A., Lopez-Picazo J.M., Hernandez A.G., Mellado B., Martinez E., Moreno F., Font A., Calvo A. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 2014, 9:e86263.
134. Berkers J., Govaere O., Wolter P., Beuselinck B., Schoffski P., van Kempen L.C., Albersen M., Van den Oord J., Roskams T., Swinnen J., Joniau S., Van Poppel H., Lerut E. A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance. J. Urol. 2013, 189:1930-1938.
135. Lin Y., Weisdorf D.J., Solovey A., Hebbel R.P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 2000, 105:71-77.
136. Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer 2002, 2:826-835.
137. Beerepoot L.V., Mehra N., Vermaat J.S., Zonnenberg B.A., Gebbink M.F., Voest E.E. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann. Oncol. 2004, 15:139-145.
138. Mancuso P., Burlini A., Pruneri G., Goldhirsch A., Martinelli G., Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001, 97:3658-3661.
139. Namdarian B., Tan K.V., Fankhauser M.J., Nguyen T.T., Corcoran N.M., Costello A.J., Hovens C.M. Circulating endothelial cells and progenitors: potential biomarkers of renal cell carcinoma. BJU Int. 2010, 106:1081-1087.
140. Bhatt R.S., Zurita A.J., O'Neill A., Norden-Zfoni A., Zhang L., Wu H.K., Wen P.Y., George D., Sukhatme V.P., Atkins M.B., Heymach J.V. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br. J. Cancer 2011, 105:112-117.
141. Zurita A.J., Jonasch E., Wu H.K., Tran H.T., Heymach J.V. Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 2009, 115:2346-2354.
142. Beaudry P., Force J., Naumov G.N., Wang A., Baker C.H., Ryan A., Soker S., Johnson B.E., Folkman J., Heymach J.V. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin. Cancer Res. 2005, 11:3514-3522.
143. Vroling L., van der Veldt A.A., de Haas R.R., Haanen J.B., Schuurhuis G.J., Kuik D.J., van Cruijsen H., Verheul H.M., van den Eertwegh A.J., Hoekman K., Boven E., van Hinsbergh V.W., Broxterman H.J. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 2009, 12:69-79.
144. Gruenwald V., Beutel G., Schuch-Jantsch S., Reuter C., Ivanyi P., Ganser A., Haubitz M. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer 2010, 10:695.
145. Farace F., Gross-Goupil M., Tournay E., Taylor M., Vimond N., Jacques N., Billiot F., Mauguen A., Hill C., Escudier B. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br. J. Cancer 2011, 104:1144-1150.
146. Perez-Gracia J.L., Prior C., Guillen-Grima F., Segura V., Gonzalez A., Panizo A., Melero I., Grande-Pulido E., Gurpide A., Gil-Bazo I., Calvo A. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br. J. Cancer 2009, 101:1876-1883.
147. Harmon C.S., DePrimo S.E., Figlin R.A., Hudes G.R., Hutson T.E., Michaelson M.D., Negrier S., Kim S.T., Huang X., Williams J.A., Eisen T., Motzer R.J. Circulating proteins as potential biomarkers of sunitinib and interferon-alpha efficacy in treatment-naive patients with metastatic renal cell carcinoma. Cancer Chemother. Pharmacol. 2014, 73:151-161.
148. Deprimo S.E., Bello C.L., Smeraglia J., Baum C.M., Spinella D., Rini B.I., Michaelson M.D., Motzer R.J. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 2007, 5:32.
149. Rini B.I., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., Stadler W.M., Hutson T.E., Margolin K., Harmon C.S., DePrimo S.E., Kim S.T., Chen I., George D.J. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26:3743-3748.
150. Porta C., Paglino C., De Amici M., Quaglini S., Sacchi L., Imarisio I., Canipari C. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 2010, 77:809-815.
151. Terakawa T., Miyake H., Kusuda Y., Fujisawa M. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol. Oncol. 2013, 31:493-498.
152. Schraml P., Struckmann K., Hatz F., Sonnet S., Kully C., Gasser T., Sauter G., Mihatsch M.J., Moch H. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J. Pathol. 2002, 196:186-193.
153. Yao M., Yoshida M., Kishida T., Nakaigawa N., Baba M., Kobayashi K., Miura T., Moriyama M., Nagashima Y., Nakatani Y., Kubota Y., Kondo K. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl. Cancer Inst. 2002, 94:1569-1575.
154. Kim J.H., Jung C.W., Cho Y.H., Lee J., Lee S.H., Kim H.Y., Park J., Park J.O., Kim K., Kim W.S., Park Y.S., Im Y.H., Kang W.K., Park K. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol. Rep. 2005, 13:859-864.
155. Smits K.M., Schouten L.J., van Dijk B.A., Hulsbergen-van de Kaa C.A., Wouters K.A., Oosterwijk E., van Engeland M., van den Brandt P.A. Genetic and epigenetic alterations in the Von Hippel-Lindau gene: the influence on renal cancer prognosis. Clin. Cancer Res. 2008, 14:782-787.
156. Rini B.I., Jaeger E., Weinberg V., Sein N., Chew K., Fong K., Simko J., Small E.J., Waldman F.M. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006, 98:756-762.
157. Choueiri T.K., Vaziri S.A., Jaeger E., Elson P., Wood L., Bhalla I.P., Small E.J., Weinberg V., Sein N., Simko J., Golshayan A.R., Sercia L., Zhou M., Waldman F.M., Rini B.I., Bukowski R.M., Ganapathi R. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. 2008, 180:860-865. (discussion 865-866).
158. van Vlodrop I.J., Baldewijns M.M., Smits K.M., Schouten L.J., van Neste L., van Criekinge W., van Poppel H., Lerut E., Schuebel K.E., Ahuja N., Herman J.G., de Bruine A.P., van Engeland M. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am. J. Pathol. 2010, 176:575-584.
159. Gebauer K., Peters I., Dubrowinskaja N., Hennenlotter J., Abbas M., Scherer R., Tezval H., Merseburger A.S., Stenzl A., Kuczyk M.A., Serth J. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br. J. Cancer 2013, 108:131-138.
160. Atschekzei F., Hennenlotter J., Janisch S., Grosshennig A., Trankenschuh W., Waalkes S., Peters I., Dork T., Merseburger A.S., Stenzl A., Kuczyk M.A., Serth J. SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence. Epigenetics 2012, 7:447-457.
161. Yamada D., Kikuchi S., Williams Y.N., Sakurai-Yageta M., Masuda M., Maruyama T., Tomita K., Gutmann D.H., Kakizoe T., Kitamura T., Kanai Y., Murakami Y. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int. J. Cancer 2006, 118:916-923.
162. Kawai Y., Sakano S., Suehiro Y., Okada T., Korenaga Y., Hara T., Naito K., Matsuyama H., Hinoda Y. Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma. Ann. Oncol. 2010, 21:1612-1617.
163. Breault J.E., Shiina H., Igawa M., Ribeiro-Filho L.A., Deguchi M., Enokida H., Urakami S., Terashima M., Nakagawa M., Kane C.J., Carroll P.R., Dahiya R. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin. Cancer Res. 2005, 11:557-564.
164. Kim J., Hwang J., Jeong H., Song H.J., Shin J., Hur G., Park Y.W., Lee S.H., Kim J. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells. Epigenetics 2012, 7:191-200.
165. Dubrowinskaja N., Gebauer K., Peters I., Hennenlotter J., Abbas M., Scherer R., Tezval H., Merseburger A.S., Stenzl A., Grunwald V., Kuczyk M.A., Serth J. Neurofilament heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response. Cancer Med. 2014, 3:300-309.
166. Peters I., Dubrowinskaja N., Abbas M., Seidel C., Kogosov M., Scherer R., Gebauer K., Merseburger A.S., Kuczyk M.A., Grunwald V., Serth J. DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies. PLoS One 2014, 9:e91440.
167. Molina A.M., Feldman D.R., Voss M.H., Ginsberg M.S., Baum M.S., Brocks D.R., Fischer P.M., Trinos M.J., Patil S., Motzer R.J. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012, 118:1868-1876.
168. Thompson R.H., Gillett M.D., Cheville J.C., Lohse C.M., Dong H., Webster W.S., Krejci K.G., Lobo J.R., Sengupta S., Chen L., Zincke H., Blute M.L., Strome S.E., Leibovich B.C., Kwon E.D. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17174-17179.
169. Thompson R.H., Dong H., Lohse C.M., Leibovich B.C., Blute M.L., Cheville J.C., Kwon E.D. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 2007, 13:1757-1761.
170. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., Gilson M.M., Wang C., Selby M., Taube J.M., Anders R., Chen L., Korman A.J., Pardoll D.M., Lowy I., Topalian S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28:3167-3175.
171. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., Leming P.D., Spigel D.R., Antonia S.J., Horn L., Drake C.G., Pardoll D.M., Chen L., Sharfman W.H., Anders R.A., Taube J.M., McMiller T.L., Xu H., Korman A.J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G.D., Gupta A., Wigginton J.M., Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
172. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., Pitot H.C., Hamid O., Bhatia S., Martins R., Eaton K., Chen S., Salay T.M., Alaparthy S., Grosso J.F., Korman A.J., Parker S.M., Agrawal S., Goldberg S.M., Pardoll D.M., Gupta A., Wigginton J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
173. Topalian S.L., Sznol M., Brahmer J.R., McDermott D.F., Smith D.C., Gettinger S.N., Taube J.M., Drake C.G., Pardoll D.M., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., Antonia S.J., Spigel D.R., Lawrence D.P., Kollia G., Gupta A.K., Wigginton J.M., Hodi F.S. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-term safety in a phase I trial. J. Clin. Oncol. 2013, 31. (Suppl.; abstr 3002).
174. Drake C.G., McDermott D.F., Sznol M., Choueiri T.K., Kluger H.M., Powderly J.D., Smith D.C., Sankar V., Gutierrez A.A., Wigginton J.M., Kollia G., Gupta A.K., Atkins M.B. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up. J. Clin. Oncol. 2013, 31. (Suppl.; abstr 4514).
175. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 1999, 17:2530-2540.
176. Heng D.Y., Xie W., Regan M.M., Warren M.A., Golshayan A.R., Sahi C., Eigl B.J., Ruether J.D., Cheng T., North S., Venner P., Knox J.J., Chi K.N., Kollmannsberger C., McDermott D.F., Oh W.K., Atkins M.B., Bukowski R.M., Rini B.I., Choueiri T.K. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 2009, 27:5794-5799.